Changes To Part D Protected Classes Uniformly Opposed At House Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
In a hearing on CMS’ proposed Medicare Part D rule, members of the Energy & Commerce Health Subcommittee agreed that the potential cost savings to Medicare through its plan to remove antidepressants, antipsychotics and immunosuppressants from Part D “protected class” status do not outweigh the downside for beneficiaries.
You may also be interested in...
Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents
Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.